Enzyvant Merges with Altavant to Advance Treatments for Rare Diseases

December 8th, 2022|Categories: Featured, Industry News|Tags: , , , , |

Enzyvant and Altavant have announced plans for a merger, which will take on the name of the former. The new company will have a facilities to manufacture regenerative medicines for rare diseases, particularly in immunology and cardiopulmonology. The combined Envyzant intends to build on its track record in the rare disease therapeutics space.

Go to Top